Case Report: Personalized peptide-based immunization in an advanced-stage prostate cancer patient with bone metastasis.

ABSTRACT: Neoantigens, which are recognized as non-self and trigger an immune response, are novel antigens generated by tumor cells. Here, we report a de novo metastatic hormone-sensitive prostate cancer (mHSPC) case, which benefited from our personalized peptide immunization named BioInformatic Tumor Address Peptides (BITAP) in a monotherapeutic setting. Our in-house bioinformatics pipeline involved identifying somatic variations, analyzing their expression, and computationally predicting novel epitopes from both metastatic and primary tumors, separately. As stand-alone therapy, the patient has been administered multiple injections of two peptide pools (BITAP-1 and BITAP-2). Several months following immunizations, a significant regression of both metastatic and primary tumor lesions was reco

SUBMITTER: Thoennissen NH 

PROVIDER: S-EPMC12321524 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature